The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Advertisement
http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html
Advertisement
Summary
The author has released its latest research "The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global HIV therapeutics market. The report analyzes the markets for HIV therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes:
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Global HIV Therapeutics Market: Introduction
2.1 GBI Research Report Guidance
3 Global HIV Therapeutics Market: Overview
3.1 Disease Overview
3.2 Market Overview
4 Global HIV Therapeutics Market: Market Characterization
4.1 Market Forecasts
4.2 Branded Versus Generics
4.3 Average Cost of Therapy
4.4 Volume
4.5 Usage Patterns
4.5.1 Diseased Population
4.5.2 Treatment Seeking Population
4.5.3 Diagnosis Population
4.5.4 Prescription Population
4.5.5 Usage Patterns
4.5.6 Geographical Distribution
4.6 HIV Therapeutics Market: Drivers and Restraints
4.7 Market Drivers
4.7.1 Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population
4.7.2 New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake
4.7.3 Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering Impact of Generics
4.8 Market Restraints
4.8.1 Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions
4.8.2 Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base
4.8.3 Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to Reduction in Drug Volumes
4.9 Market Trend
4.9.1 Incidence and Prevalence Rates are Increasing at a Slow Rate
4.9.2 Many New Companies are Actively Pursuing Different Classes of Drugs in Their Pipeline
4.9.3 Although DTC Advertising is Aimed at Increasing Awareness, it is Attracting Criticism for Incorrect Depiction of Therapeutic Benefits of Treatment Options
4.9.4 Current Reimbursement Scenario is Positive for HIV as Countries Reimburse Almost All of the Costs Associated with HIV Drugs
4.9.5 Regulatory Scenario for HIV Drugs is Positive and Many Countries Facilitate Quicker Review for HIV Drug Applications
5 Global HIV Therapeutics Market: The US Market
5.1 Market Forecasts
5.2 Average cost of Therapy
5.3 Volume
5.4 Usage Patterns
5.4.1 Diseased Population
5.4.2 Treatment Seeking Population
5.4.3 Diagnosis Population
5.4.4 Prescription Population
5.4.5 Usage Patterns
6 Global HIV Therapeutics Market: Europe Market
6.1 Market Forecasts
6.2 Average Cost of Therapy
6.3 Volume
6.4 Usage patterns
6.4.1 Diseased Population
6.4.2 Treatment Seeking Population
6.4.3 Diagnosis Population
6.4.4 Prescription Population
6.4.5 Usage Patterns
7 Global HIV Therapeutics Market: Japan Market
7.1 Market Forecasts
7.2 Average Cost of Therapy
7.3 Volume
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Usage Patterns
8 Global HIV Therapeutics Market: Unmet Need
8.1 Different Classes of Drugs
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
8.1.3 Protease Inhibitors
8.1.4 Viral Fusion (or Entry) Inhibitors
8.1.5 HIV Integrase Strand Transfer Inhibitors
8.1.6 Multi-class Combination Products
8.2 Unmet Need Analysis
8.2.1 HIV Drugs are Low in Efficacy as None of the Drugs Provide a Cure for the Disease However Newer Multi Class Combination Drugs Can Achieve Undetectable Level of HIV
8.2.2 When Compared to the Adverse Symptoms of HIV Infection Progression, the HIV Medications are Relatively Safe and Have Serious Side Effects Rarely
8.2.3 Average Cost of HIV Therapy is High, Leading to a Need for a More Cost Effective Treatment Option
8.3 Pipeline Analysis
8.3.1 Phase I
8.3.2 Phase II
8.3.3 Phase III
9 Global HIV Therapeutics Market: Competitive Landscape
9.1 Evolving Competitive Landscape
9.2 Market Share Analysis
9.2.1 Atripla, Truvada and Isentress are the HIV brands that will Drive the Market and Competition
9.3 Key Product Analysis
9.3.1 Truvada
9.3.2 Atripla
9.3.3 Viread
9.3.4 Isentress
9.3.5 Trizivir
9.3.6 Kaletra
9.3.7 Reyataz
9.3.8 Combivir
9.3.9 Epzicom/Kivexa
9.3.10 Sustiva Franchise
9.4 Competitive Profiling
9.4.1 Gilead
9.4.2 GlaxoSmithKline (GSK)
9.4.3 Bristol-Myers Squibb (BMS)
9.4.4 Abbott Laboratories
9.4.5 Merck
9.4.6 Pfizer
10 Global HIV Therapeutics Market: Strategic Consolidations
10.1 Overview
10.1.1 Total Deals by Type and Geography
10.2 Mergers and Acquisitions
10.3 Licensing Agreements
10.3.1 Preclinical
10.3.2 Phase II
10.3.3 Phase III
10.3.4 Approved
11 Global HIV Therapeutics Market: Conclusion
12 Global HIV Therapeutics Market: Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
12.3.4 Forecasts
12.3.5 Expert Panel Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Sources
1.1 List of Tables
Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2000-2008
Table 2: HIV Market, Global, Revenue ($m), 2008-2015
Table 3: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008
Table 4: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015
Table 5: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
Table 6: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
Table 7: HIV Therapeutics Market, Global, Volume (million), 2000-2008
Table 8: HIV Therapeutics Market, Global, Volume (million), 2008-2015
Table 9: HIV Therapeutics Market, Global, Diseased Population, 2000-2008
Table 10: HIV Therapeutics Market, Global, Diseased Population, 2008-2015
Table 11: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2008
Table 12: HIV Therapeutics Market, Global, Treatment Seeking Population, 2008-2015
Table 13: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2008
Table 14: HIV Therapeutics Market, Global, Diagnosis Population, 2008-2015
Table 15: HIV Therapeutics Market, Global, Prescription Population, 2000-2008
Table 16: HIV Therapeutics Market, Global, Prescription Population, 2008-2015
Table 17: HIV Therapeutics Market, Global, Usage Patterns, 2000-2008
Table 18: HIV Therapeutics Market, Global, Usage Patterns, 2008-2015
Table 19: HIV Therapeutics Market, Global, Market Drivers, 2008
Table 20: HIV Therapeutics Market, Global, Market Restraints, 2008
Table 21: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2008-15
Table 22: HIV Therapeutics Market, US, Revenues ($m), 2000-2008
Table 23: HIV Therapeutics Market, US, Revenue ($m), 2008-2015
Table 24: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2008
Table 25: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2008-2015
Table 26: HIV Therapeutics Market, US, Volume (million), 2000-2008
Table 27: HIV Therapeutics Market, US, Volume (million), 2008-2015
Table 28: HIV Therapeutics Market, US, Diseased Population, 2000-2008
Table 29: HIV Therapeutics Market, US, Diseased Population, 2008-2015
Table 30: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2008
Table 31: HIV Therapeutics Market, US, Treatment Seeking Population, 2008-2015
Table 32: HIV Therapeutics Market, US, Diagnosis Population, 2000-2008
Table 33: HIV Therapeutics Market, US, Diagnosis Population, 2008-2015
Table 34: HIV Therapeutics Market, US, Prescription Population, 2000-2008
Table 35: HIV Therapeutics Market, US, Prescription Population, 2008-2015
Table 36: HIV Therapeutics Market, US, Usage Patterns, 2000-2008
Table 37: HIV Therapeutics Market, US, Usage Patterns, 2008-2015
Table 38: HIV Therapeutics Market, Europe, Revenues ($m), 2000-2008
Table 39: HIV Therapeutics Market, Europe, Revenue ($m), 2008-2015
Table 40: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2000-2008
Table 41: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2008-2015
Table 42: HIV Therapeutics Market, Europe, Volume (million), 2000-2008
Table 43: HIV Therapeutics Market, Europe, Volume (million), 2008-2015
Table 44: HIV Therapeutics Market, Europe, Diseased Population, 2000-2008
Table 45: HIV Therapeutics Market, Europe, Diseased Population, 2008-2015
Table 46: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008
Table 47: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2008-2015
Table 48: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2008
Table 49: HIV Therapeutics Market, Europe, Diagnosis Population, 2008-2015
Table 50: HIV Therapeutics Market, Europe, Prescription Population, 2000-2008
Table 51: HIV Therapeutics Market, Europe, Prescription Population, 2008-2015
Table 52: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2008
Table 53: HIV Therapeutics Market, Europe, Usage Patterns, 2008-2015
Table 54: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2008
Table 55: HIV Therapeutics Market, Japan, Revenue ($m), 2008-2015
Table 56: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2008
Table 57: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2008-2015
Table 58: HIV Therapeutics Market, Japan, Volume (million), 2000-2008
Table 59: HIV Therapeutics Market, Japan, Volume (million), 2008-2015
Table 60: HIV Therapeutics Market, Japan, Diseased Population, 2000-2008
Table 61: HIV Therapeutics Market, Japan, Diseased Population, 2008-2015
Table 62: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2008
Table 63: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2008-2015
Table 64: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2008
Table 65: HIV Therapeutics Market, Japan, Diagnosis Population, 2008-2015
Table 66: HIV Therapeutics Market, Japan, Prescription Population, 2000-2008
Table 67: HIV Therapeutics Market, Japan, Prescription Population, 2008-2015
Table 68: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2008
Table 69: HIV Therapeutics Market, Japan, Usage Patterns, 2008-2015
Table 70: HIV Market, Global, Different Classes of Drugs
Table 71: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2008
Table 72: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2008
Table 73: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2008
Table 74: HIV Therapeutics Market, Global, Major Drugs and Manufacturers, 2008
Table 75: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008
Table 76: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008
Table 77: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008
Table 78: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008
Table 79: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008
1.2 List of Figures
Figure 1: HIV Therapeutics Market, Global, Market Overview, 2008
Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2015
Figure 3: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
Figure 4: HIV Therapeutics Market, Global, Volume (million), 2000-2015
Figure 5: HIV Therapeutics Market, Global, Diseased Population, 2000-2015
Figure 6: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2015
Figure 7: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2015
Figure 8: HIV Therapeutics Market, Global, Prescription Population, 2000-2015
Figure 9: HIV Therapeutics Market, Global, Usage Patterns, 2000-2015
Figure 10: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2000-2015
Figure 11: HIV Therapeutics Market, Global, Geographical Outlook, 2008
Figure 12: HIV Therapeutics Market, Global, Market Indicators, 2008
Figure 13: HIV Therapeutics Market, Global, Key Market Events, 2008-2015
Figure 14: HIV Therapeutics Market, US, Revenue ($m), 2000-2015
Figure 15: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2015
Figure 16: HIV Therapeutics Market, US, Volume (million), 2000-2015
Figure 17: HIV Therapeutics Market, US, Diseased Population, 2000-2015
Figure 18: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2015
Figure 19: HIV Therapeutics Market, US, Diagnosis Population, 2000-2015
Figure 20: HIV Therapeutics Market, US, Prescription Population, 2000-2015
Figure 21: HIV Therapeutics Market, US, Usage Patterns, 2000-2015
Figure 22: HIV Therapeutics Market, Europe, Revenue ($m), 2000-2015
Figure 23: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 2000-2015
Figure 24: HIV Therapeutics Market, Europe, Volume (million), 2000-2015
Figure 25: HIV Therapeutics Market, Europe, Diseased Population, 2000-2015
Figure 26: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2015
Figure 27: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2015
Figure 28: HIV Therapeutics Market, Europe, Prescription Population, 2000-2015
Figure 29: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2015
Figure 30: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2015
Figure 31: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2015
Figure 32: HIV Therapeutics Market, Japan, Volume (million), 2000-2015
Figure 33: HIV Therapeutics Market, Japan, Diseased Population, 2000-2015
Figure 34: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015
Figure 35: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2015
Figure 36: HIV Therapeutics Market, Japan, Prescription Population, 2000-2015
Figure 37: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2015
Figure 38: HIV Therapeutics Market, Global, Analysis of Unmet Needs for Major Drug Class, 2008
Figure 39: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2008
Figure 40: HIV Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues, 2006-08
Figure 41: HIV Therapeutics Market, Global, Competitive Analysis of Top 4 Manufacturers, 2006-08
Figure 42: HIV Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Figure 43: HIV Therapeutics Market, Global, Benchmark of Top 10 Brands - 2008
Figure 44: HIV Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2009
Figure 45: HIV Therapeutics Market, GSK, HIV Revenue as Percentage of Total Revenue, 2009
Figure 46: HIV Therapeutics Market, BMS, HIV Revenue as Percentage of Total Revenue, 2009
Figure 47: HIV Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2009
Figure 48: HIV Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2009
Figure 49: HIV Therapeutics Market, Global, Deals by Geography and Type, 2008
Figure 50: HIV Therapeutics Market, Global, M&A Deals, 2008
Figure 51: HIV Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-09
Figure 52: GBI Research Methodology
Figure 53: GBI Research Market Forecasting Model
Companies mentioned
Gilead
GlaxoSmithKline (GSK)
Bristol-Myers Squibb (BMS)
Abbott Laboratories
Merck
Pfizer
To order this report: Pharmaceutical Industry: The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
More Market Research Report
-- Annualized market data for the HIV therapeutics market from 2000 to 2008, forecast forward to 2015 -- Analysis of the HIV therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan -- Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns -- Key drivers and barriers that have a significant impact on the market -- Coverage of pipeline molecules in various phases of drug development -- Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc -- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market
SOURCE Reportlinker
